BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 31088509)

  • 21. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
    Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
    Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of severe renal disease in anti-neutrophil-cytoplasmic-antibody-associated vasculitis: the place of rituximab and plasma exchange?
    Morel P; Karras A; Porcher R; Belenfant X; Audard V; Rafat C; Hanouna G; Beaudreuil S; Vilain C; Hummel A; Terrier B; Pillebout E; Groh M; Jouenne R; Dhote R; Fain O; Ponsoye M; Noel N; Limal N; Puéchal X; Le Jeunne C; Guillevin L; Mouthon L; Régent A
    Rheumatology (Oxford); 2022 Oct; 61(10):4056-4064. PubMed ID: 35108368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
    Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report.
    Harris C; Marin J; Beaulieu MC
    BMC Nephrol; 2018 Jun; 19(1):152. PubMed ID: 29954345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
    Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinico-pathological features and outcomes of patients with propylthiouracil-associated ANCA vasculitis with renal involvement.
    Chen Y; Bao H; Liu Z; Zhang H; Zeng C; Liu Z; Hu W
    J Nephrol; 2014 Apr; 27(2):159-64. PubMed ID: 24570072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant.
    Murakami C; Manoharan P; Carter-Monroe N; Geetha D
    Transpl Int; 2013 Dec; 26(12):1225-31. PubMed ID: 24118474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
    Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
    N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High anti-neutrophil cytoplasmic antibody titers are associated with the requirement of permanent dialysis in patients with myeloperoxidase-ANCA-associated vasculitis.
    Yen CL; Tian YC; Wu HH; Tu KH; Liu SH; Lee CC; Fang JT; Yang CW; Li YJ
    J Formos Med Assoc; 2019 Oct; 118(10):1408-1415. PubMed ID: 31133523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
    Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
    Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab for ANCA-associated vasculitis in the setting of severe infection.
    Gregersen JW; Chaudhry A; Jayne DR
    Scand J Rheumatol; 2013; 42(3):207-10. PubMed ID: 23286789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case report: de novo ANCA-associated vasculitis after kidney transplantation treated with rituximab and plasma exchange.
    Sagmeister MS; Weiss M; Eichhorn P; Habicht A; Habersetzer R; Fischereder M; Schönermarck U
    BMC Nephrol; 2018 Oct; 19(1):270. PubMed ID: 30340563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double positivity for antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane antibody could predict end-stage renal disease in ANCA-associated vasculitis: a monocentric pilot study.
    Yoo BW; Ahn SS; Jung SM; Song JJ; Park YB; Lee SW
    Clin Rheumatol; 2020 Mar; 39(3):831-840. PubMed ID: 31802348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy of protein A immunoadsorption therapy on severe ANCA-associated vasculitis renal injury.
    Song J; Liu H; Chen X; Zhou L; Sun C; Yuan F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jul; 48(7):1026-1032. PubMed ID: 37724405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The neutrophil-to-lymphocyte ratio as a marker of vasculitis activity, severe infection and mortality in anca-associated vasculitis: A retrospective study.
    Fonseca JA; Gameiro J; Duarte I; Jorge S; Lopes JA
    Nefrologia (Engl Ed); 2021; 41(3):321-328. PubMed ID: 36165341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
    Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
    Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of renal ANCA-associated vasculitides.
    Rowaiye OO; Kusztal M; Weyde W; Klinger M
    Postepy Hig Med Dosw (Online); 2016 Jun; 70(0):654-67. PubMed ID: 27356598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uncommon presentations in ANCA vasculitis: clinical characteristics and outcomes.
    Katikineni VS; Kant S; Gapud EJ; Antiochos B; Manno RL; Phillips M; Seo P; Geetha D
    Clin Rheumatol; 2019 Aug; 38(8):2195-2199. PubMed ID: 31037456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Acute Kidney Injury: Short-Term Recovery Predicts Long-Term Outcome.
    Huang X; Chen L; Lan L; Ren P; Ni A; Ma Y; Wang Y; Zhu Y; Xu Y; Chen J; Han F
    Front Immunol; 2021; 12():641655. PubMed ID: 34305886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics and Visual Outcome of Refractory Retinal Vasculitis Associated With Antineutrophil Cytoplasm Antibody-Associated Vasculitides.
    Lin M; Anesi SD; Ma L; Ahmed A; Small K; Foster CS
    Am J Ophthalmol; 2018 Mar; 187():21-33. PubMed ID: 29258731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.